Senger DR, Perruzzi CA, Gracey CF et al. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Res 1988; 48: 5770–4.
Chambers AF, Tuck AB. Ras-responsive genes and tumor metastasis. Crit Rev Oncogen 1993; 4: 95–114.
Denhardt DT, Guo X. Osteopontin a protein with diverse functions. FASEB J 1993; 7: 1475–82.
Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997; 17: 1–15.
Uede T, Katagiri Y, Iizuka J et al. Osteopontin, a coordinator of host defense system: A cytokine or an extracellular adhesive protein? Microbiol Immunol 1997; 41: 641–8.
Rittling SR, Denhardt DT. Osteopontin function in pathology: Lessons from OPN-deficient mice. Expt Nephrology 1999; 7: 103–13.
Noda M, Denhardt DT. Osteopontin. In Bilezikian JP, Raisz LG, Rodan GA (eds): Principles of Bone Biology, 2nd ed. San Diego: Academic Press 2002.
Chabas D, Baranzini SE, Mitchell D et al. The influence of the proin-flammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731–5.
Yumoto K, Ishijima M, Rittling SR et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibodyinduced arthritis in mice. Proc Natl Acad Sci USA 2002; 99: 4556–61.
Giachelli CM, Steitz S. Osteopontin: A versatile regulator of inflammation and biomineralization. Matrix Biol 2000; 19: 615–22.
Weber GF. The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim Biophys Acta 2001; 1552: 61–85.
Denhardt DT, Noda M, O’Regan AW et al. Osteopontin-a means to cope with environmental insults: Regulation of inflammation tissue remodeling and cell survival. J Clin Invest 2001; 107: 1055–61.
Tuck AB, Chambers AF. The role of osteopontin in breast cancer: Clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001; 6: 419–29.
Furger KA, Menon RK, Tuck AB et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1: 621–32.
Rittling SR, Chen Y, Feng F, Wu Y. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002; 277: 9175–82.
Katagiri YU, Sleeman J, Fujii H et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59: 219–26.
Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11: 279–303.
Suzuki K, Zhu B, Rittling SR et al. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 2002; 17:1486–97.
Denhardt DT, Lopez CA, Rollo EE et al. Osteopontin-induced modi-fications of cellular functions. Ann NY Acad Sci 1995; 760: 127–42.
Noiri E, Dickman K, Miller F et al. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int 1999; 56: 74–82.
Scatena M, Almeida M, Chaisson ML et al. NF-κB mediates ανβЗ integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083–93.
Lin Y-H, Yang-Yen H-F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol-3-kinase/Akt signaling pathway. J Biol Chem 2001; 276: 46024–30.
Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cellul Biochem 2002; 85: 728–36.
Senger DR, Asch BB, Smith BD et al. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 1983; 302: 714–5.
Brown LF, Papadopoulos-Sergiou A, Berse B et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610–23.
Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin two bone matrix proteins in human breast cancer. Am J Pathol 1996; 146: 95–100.
Casson AG, Wilson SM, McCart JA et al. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 1997; 72: 739–45.
Gillespie MT, Thomas RJ, Zhou PU et al. Calcitonin receptors bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997; 10: 812–815.
Tuck AB, O’Malley FP, Singhal H et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79: 502–8.
Sung V, Gilles C, Murray A et al. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits invasive and metastatic phenotype. Exp Cell Res 1998; 241: 273–84.
Sharp JA, Sung V, Slavin J et al. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest 1999; 79: 869–77.
Price JE, Polyzos A, Zhang RD et al. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717–21.
Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991; 11: 204–15.
Price JE. Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 1996; 39: 93–102.
Bautista DS, Xuan JW, Hota C et al. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994; 269: 23280–5.
Tuck AB, Arsenault DM, O’Malley FP et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999; 18: 4237–46.
Yoneda T, Williams PJ, Niewolna M. Promotion of angiogenesis and enhancement of breast cancer metastasis to bone. Bone 1998; 23/5S: S201.
Mukhopadhyay R, Price JE. Stable expression of antisense osteopontin inhibits the growth of human breast cancer cells. Proc Am Assoc Cancer Res 1999; 40: 448.
Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989; 9: 1291–300.
Chambers AF, Tuck AB. Osteopontin: A Ras-regulated gene that contributes to tumor metastasis. InWelch DR (ed): Cancer Metastasis-Related Genes. Dordrecht, The Netherlands: Kluwer Academic Publishers 2002; 231–46.
Hwang S-M, Lopez CA, Heck DE et al. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 1994; 269: 711–5.
Rollo EE, Laskin DL, Denhardt DT. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW2647 macrophages. J Leuk Biol 1996; 60: 397–404.
Scott JA, Weir ML, Wilson SM et al. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. AmJ Physiol 1998; 275: H2258–65.
Denhardt DT, Chambers AF. Overcoming obstacles to metastasis — defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994; 56: 48–51.
Yue TL, McKenna PJ, Ohlstein EH et al. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by β3 integrin. Exp Cell Res 1994; 214: 459–64.
Liaw L, Skinner MP, Raines EW et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins: Role of ανβ3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995; 95: 713–24.
Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1996; 1314: 13–24.
Weintraub AS, Giachelli CM, Krauss RS et al. Autocrine secretion of osteopontin by vascular smooth muscle cells regulates their adhesion to collagen gels. Am J Path 1996; 149: 259–72.
Tuck AB, Elliott BE, Hota C et al. Osteopontin-induced integrindependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor. J Cell Biochem 2000; 78: 465–75.
Tuck AB, Hota C, Chambers AF. Osteopontin-induced increase in human mammary epithelial cell invasiveness is urokinase (uPa)-dependent. Breast Cancer Res Treat 2001; 70: 197–204.
Takahashi F, Akutagawa S, Fukumoto H et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 2002; 98: 707–12.
Chambers AF, Wilson SM, Kerkvleit N et al. Osteopontin expression in lung cancer. Lung Cancer 1996; 15: 311–23.
Rudland PS, Platt-Higgins A, El-Tanani M et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62: 3417–27.
Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671–9.
Gotoh M, Sakamoto M, Kanetaka K et al. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002; 52: 19–24.
Agrawal D, Chen T, Irby R et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513–21.
Bautista DS, Saad Z, Chambers AF et al. Quantification of osteopontin in human plasma with an ELISA: Basal levels in pre-and postmenopausal women. Clin Biochem 1996; 29: 231–9.
Singhal H, Bautista DS, Tonkin KS et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605–11.
Hotte SJ, Winquist, EW, Stitt L et al. Plasma osteopontin: Associations with survival and metastasis to bone in men with hormone refractory prostate cancer. Cancer, 2002; 95: 506–512.
Fedarko NS, Fohr B, Robey PG et al. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complementmediated attack. J Biol Chem 2000; 275: 16666–72.
Fedarko NS, Jain A, Karadag A et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060–6.
O’Regan A, Fleming C. Comment on: JAMA 2002, 287: 1671-9. Osteopontin as a biomarker for ovarian cancer. JAMA 2002; 287: 3208–10.
Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206–15.
Feng F, Rittling SR. Mammary tumor development in MMTV-cmyc/ MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res Treat 2000; 63: 71–9.
Wu Y, Denhardt DT, Rittling SR. Osteopontin expression is required for full expression of the transformed phenotype by the Ras oncogene. Br J Cancer 2000; 83: 156–63.
Nemoto H, Rittling SR, Yoshitake H et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 2001; 16: 652–9.
Orphanides G, Reinberg DA. Unified theory of gene expression. Cell 2002; 108: 439–52.
Hunter T. Oncoprotein networks. Cell 1997; 88: 333–46.
Webb CP, Vande Woude GF. Genes that regulate metastasis and angiogenesis. J Neurooncol 2000; 50: 71–87.
Welch DR, Steeg PS, Rinker-Schaeffer CW. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2000; 2: 408–16.
Denhardt DT, Noda M. Osteopontin expression and function: Role in bone remodeling. J Cell Biochem 1998; Suppl 30/31: 92–102.
Craig AM, Bowden GT, Chambers AF et al. Secreted phosphoprotein mRNA is induced during multistage carcinogenesis in mouse skin and correlates with the metastatic potiential of murine fibroblasts. Int J Cancer 1990; 46: 133–7.
Yoon JW, Kita Y, Frank DJ et al. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 2002; 277: 5548–55.
Davies BR, Barraclough R, Rudland PS. Induction of metastatic ability in a stably diploid benign rat mammary epithelial cell line by transfection with DNA from human malignant breast carcinoma cell lines. Cancer Res 1994; 54: 2785–93.
Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996; 13: 97–104.
Chen H, Ke Y, Oates AJ et al. Isolation of and effector for metastasisinducing DNAs from a human metastatic carcinoma cell line. Oncogene 1997; 14: 1581–8.
El-Tanani M, Barraclough R, Wilkinson MC et al. Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4. Oncogene 2001; 20: 1793–7.
El-Tanani M, Barraclough R, Wilkinson MC et al. Metastasisinducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res 2001; 61: 5619–29.
Wang D, Yamamoto S, Hijiya N et al. Transcriptional regulation of the human osteopontin promoter: Functional analysis and DNA-protein interactions. Oncogene 2000; 19: 5801–9.
Malyankar UM, Hanson R, Schwartz SM et al. Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells. Exp Cell Res 1999; 250:535–47.
Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682–9.
Varghese HJ, Davidson MT, MacDonald IC et al. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res 2002; 62: 887–91.
Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 2001; 333: 267–83.
Guo X, Zhang YP, Mitchell DA et al. Identification of a ras-activated enhancer in the mouse osteopontin gene and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol 1995; 15: 476–87.
Craig AM, Denhardt DT. The murine gene encoding secreted phosphoprotein (osteopontin): Promoter structure activity and induction in vivo by estrogen and progesterone. Gene 1991; 100: 163–71.
Zhang Q, Wrana JL, Sodek J. Characterization of the promoter region of the porcine opn (osteopontin secreted phosphoprotein 1) gene. Eur J Biochem 1992; 207: 649–59.
Hijiya N, Setoguchi M, Matsuura K et al. Cloning and characterization of the human osteopontin gene and its promoter. Biochem J 1994; 303: 255–62.
Rafidi K, Simkina I, Johnson E et al. Characterization of the chicken osteopontin-encoding gene. Gene 1994; 140: 163–9.
Ridall AL, Daane EL, Dickinson DP et al. Characterization of the rat osteopontin gene. Evidence for two vitamin D response elements. Ann NY Acad Sci 1995; 760: 59–66.
Webb CP, van Aelst L, Wigler MH et al. Signaling pathways in Rasmediated tumorigenicity and metastasis. Proc Natl Acad Sci USA 1998; 95: 8773–8.
Morishita R, Higaki J, Tomita N et al. Application of transcription factor ‘decoy’ strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82: 1023–8.
Tomita S, Tomita N, Yamada T et al. Transcription factor decoy to study the molecular mechanism of negative regulation of renin gene expression in the liver in vivo. Circ Res 1999; 84: 1059–66.
Van Golen KL, Wu Z-F, Qial T et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60: 5832–8.
Tuteja R, Tuteha N. Ku Autoantigen: A multifactorial DNA-binding protein. Crit Rev Biochem Mol Biol 2000; 35: 1–33.
Singh H, Sen R, Baltimore D et al. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature 1986; 319: 154–8.